Arthritis approach |
check point inh 2 |
Hip & Knee pain |
HLA and rheumatic diseases |
JIA from pathogenesis to treatment |
Systemic Lupus Erythematosus |
SLE pathogenesis |
RPC |
osteonecrosis |
null |
null(2) |
knee and hip pain |
Low Back Pain approach |
METABOLIC |
Lupus treatment strategies |
Cutaneous manifestations of rheumatic diseases |
Overlap syndrome |
Spondyloarthritis pathogenesis |
Ankylosing Spondylitis |
Psoriatic Arthritis |
Juvenile Dermatomyositis |
Juvenile scleroderma |
IBD associated arthritis |
Reactive Arthritis(1) |
Pathogenesis of RA |
Antiphospholipid syndrome |
Pathogenesis of RA revisied(6) |
RA treatment(6) |
Sarcoidosis from pathogenesis to treatment |
Spondyloarthritis updates |
Endocrine diseases & msk manifestations |
Osteonecrosis from a-z(1) |
Wilson’s disease |
Innate immunity & Rheumatic diseases |
http://rhd.sbmu.ac.ir/uploads/oldfile/4 |
Adaptive immunity |
Antiphospholipid management |
Sjogren’s syndrome from etiopathogenesis to therapy(2) |
Neuropsychiatric lupus |
Sjogren’s syndrome from etiopathogenesis to therapy 2 |
Septic arthritis |
Anticoagulant drugs(2) |
Rheumatoid Arthritis & lung involvement |
Scleroderma pathogenesis |
Systemic Sclerosis organ based management II |
Hypersensitivity reactions to biologics |
Idiopathic inflammatory myositis(7) |
Idiopathic inflammatory myositis(8) |
MoshakhasatDore195407-35df3 |
Spondyloarthritis treatment updates(4) |
Spondyloarthritis treatment updates(5) |
Takayasu arteitis(3) |
Osteoarthritis pathogenesis(2) |
IVIG clinical implications(1) |
Familial autoinflammatory syndromes(1) |
Familial autoinflammatory syndromes(2) |
Psoriatic arthritis radiologic findings 2(2) |
Ig G4 related disease 2 |
Osteoarthritis radiologic scoring system |
Giant cell & Takayasu arteritis |
Covid and vasculitis |
CKD and osteoporosis management |
Dendritic cells and rheumatic diseases(1) |
Chest radiology infections vs ILD |
Giant cell & Takayasu arteritis 2 |
Mononuclear phagocyte role in rheumatic diseases |
Endocarditis bacterial vc nonbacterial(1) |
Heart failure approach |
Immune complex mediated small vessel vasculitis |
Rituximab in rheumatic diseases |
Amyloidosis |
Mast Cells and rheumatic diseases |
SPARCC SIJ scoring |
|
|